Algiax Is Ready to Go Into Proof-of-Concept for AP-325 and Welcomes New Investors

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Algiax Pharmaceuticals, a clinical-stage biotechnology company focused on development of GABAA receptor modulators for neuropathic pain and other indications with unmet medical need, announced to have secured financing for its development program including a proof-of-concept Phase IIa study named CURE for its lead compound AP-325 in chronic neuropathic pain.

The company has raised 5.5 million Euro from existing investors as well as from two new investors, namely OCCIDENT, an international investment company with offices in Zug and Munich, and an undisclosed German family office.

We are very happy about the continuous high trust of our investors in our company and our clinical development program said Ingo Lehrke, CEO of Algiax. Additionally, with OCCIDENT we have convinced a professional investment team of the potential of our lead candidate AP-325.

Cdric Barra, Investment Manager at OCCIDENT added: We are convinced that Algiax has a pioneering approach in the treatment of neuropathic pain. Algiax is developing drug candidates that not only promise a significant improvement in patients’ quality of life, but are also an important approach in the fight against the opiate crisis, as the drugs do not cross the blood-brain barrier. Therefore, they have significantly fewer side effects and addiction potential than conventional approaches

The company further announced that it has filed a clinical trial application for its phase IIa clinical trial CURE in the EU and plans to start patient recruitment in beginning of 2020. We have chosen to do our proof-of-concept study in patients suffering from chronic post-surgical pain. said Dr. Koopmans, CSO of Algiax. There is a high medical need in this very large patient group. In various relevant pain models AP-325 showed excellent efficacy and we expect to translate these findings into medical practice.

About Algiax (www.algiax.com) Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011. It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need. Algiax lead candidate AP-325 is a small-molecule GABAA receptor modulator in clinical development as a therapy for neuropathic pain.

Next to AP-325 Algiax has discovered novel GABAA receptor modulator compounds called Thioacrylamide (ThAc) derivatives. The company is advancing a selection of ThAcs derivatives from its discovery to preclinical characterization.

About OCCIDENT (www.occident.group) OCCIDENT is an international, privately held investment company based in Zug and Munich, whose aim is to manage its own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through its investments.

OCCIDENT sees itself as a long-term oriented enabler for innovative start-ups and visionary founders. Its complementary team of experts is fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people’s lives.

Press contact:

Algiax Pharmaceuticals GmbH

Dr. Ingo Lehrke, CEO

[email protected]



C├ędric Barra

[email protected]

+49 89 21539980